

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

**MONTHLY UPDATE ON BANKRUPTCY LIQUIDATION OF A SUBSIDIARY OF THE COMPANY
PURSUANT TO RULE 704(23) OF THE LISTING MANUAL**

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company” and together with its subsidiaries, the “Group”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to the announcements dated 14 August 2025, 29 August 2025, 30 September 2025, 30 October 2025 and 28 November 2025 made by the Company in relation to the bankruptcy liquidation (破产清算) of Tianjin Shin Poong Pharmaceutical Co., Ltd. (天津新丰制药有限公司), a 55%-owned subsidiary incorporated in the People's Republic of China (the “**Previous Announcements**”).

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Previous Announcements.

2. MONTHLY UPDATE PURSUANT TO RULE 704(23) OF THE LISTING MANUAL

The Board wishes to update that there have been no material developments in relation to the bankruptcy proceedings which may have a significant impact on the financial position of the Company since the Company's last monthly update on 28 November 2025.

The Company will continue to monitor the progress of the bankruptcy proceedings, maintain active communication with the Court and the Administrator, and take all reasonable steps to safeguard the interests of the Company and its shareholders. It will also continue to provide monthly updates pursuant to Rule 704(23) of the Listing Manual, and make further announcement(s) as and when appropriate in accordance with applicable laws, regulations and rules.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
31 December 2025